Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions

12 november 2026 bijgewerkt door: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing

This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.

Studie Overzicht

Studietype

Ingrijpend

Inschrijving (Geschat)

650

Fase

  • Fase 3

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

      • Beijing, China, 100730
        • Beijing Tongren Hospital, Capital Medical University
        • Contact:
    • Hubei
      • Wuhan, Hubei, China, 430030
        • Tongji Hospital, Tongji Medical College of Hust
        • Contact:
    • Shanxi
      • Taiyuan, Shanxi, China, 030032
        • Shanxi Bethune Hospital

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar tot 60 jaar (Volwassen)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Male or female participants aged 18-60 years, inclusive.
  2. Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
  3. Participants who are able to understand the study and voluntarily provide written informed consent.

Exclusion Criteria:

  1. History of needle-related syncope or vasovagal reactions to the sight of blood.
  2. Pregnant or breastfeeding women.
  3. History of malignant tumors.
  4. Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
  5. Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
  6. Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
  7. Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
  8. Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
  9. Systemic use of immunosuppressants within 14 days before SPT.
  10. Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
  11. Treatment with dupilumab or similar agents within 3 months before SPT.
  12. Treatment with omalizumab or similar agents within 5 months before SPT.
  13. Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
  14. Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
  15. Positive skin scratch test for dermographism during screening.
  16. Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
  17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Skin Prick Test Group

All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Ragweed Pollen (3,500 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (19,500 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (19,500 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (39,000 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (39,000 DU/mL)
Tijdsspanne: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Adverse Events
Tijdsspanne: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.

Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable.

From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
Changes in Vital Signs from Baseline
Tijdsspanne: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.

Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
Changes in Physical Examination Findings from Baseline
Tijdsspanne: At screening and on Day 2 of the study or at early termination.

Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Hematology Parameters from Baseline
Tijdsspanne: At screening and on Day 2 of the study or at early termination.

Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Urinalysis Parameters from Baseline
Tijdsspanne: At screening and on Day 2 of the study or at early termination.

Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

11 november 2026

Primaire voltooiing (Geschat)

1 juni 2027

Studie voltooiing (Geschat)

1 oktober 2027

Studieregistratiedata

Eerst ingediend

5 november 2026

Eerst ingediend dat voldeed aan de QC-criteria

12 november 2026

Eerst geplaatst (Werkelijk)

18 november 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

12 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • WOLWO-D1-0III32-1

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren